Investigational drug · Phase 3
AVTX-803
Also called: L-Fucose
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Leukocyte Adhesion Deficiency.
Phase 3Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AVTX-803"
First trial start
2022
Jul 28, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AVTX-803", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leukocyte Adhesion Deficiency
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "AVTX-803" as an intervention, largest first.
- A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type IIPivotal-lookingRecruiting
AUG TherapeuticsIndustry
NCT05462587 · 4 participants (planned) · Start Jul 28, 2022 · Primary completion Nov 30, 2026
Drug: AVTX-803 (L-Fucose) · For: Leukocyte Adhesion Deficiency
Sites: Rochester, Minnesota
- An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type IIPivotal-lookingRecruiting
AUG TherapeuticsIndustry
NCT05754450 · 2 participants (planned) · Start Apr 10, 2023 · Primary completion Dec 31, 2026
Drug: AVTX-803 · For: Leukocyte Adhesion Deficiency
Sites: Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- Fluorescent labeling of lysosomal α-L-fucosidase using an activity-based near-infrared (NIR) fluorogenic probe.
Kim Y, Lee CH, Shin I · Anal Chim Acta 2026
- Identification and characterization of a novel α-L-fucosidase from Desertivirga arenae for efficient L-fucose biosynthesis in metabolically engineered Escherichia coli.
Meng J, Li A, Lu Z, et al. · Enzyme Microb Technol 2026
- Systematic modular engineering of genome-integrated Escherichia coli MG1655 for high-level 2'-fucosyllactose production.
Chen R, Yang L, Wang H, et al. · Enzyme Microb Technol 2026
- L-fucose-dependent biofilm formation by Escherichia coli enhances polymicrobial interactions and antibiotic tolerance on urinary catheters.
Taddei SM, Deka N, Marin A, et al. · Biofilm 2026
- Broadening the Substrate Specificity of a Sugar Kinase to Span l- and d-Sugars for Coupled Activation Reactions.
Kim H, Koid A, Lupoli TJ · Biochemistry 2026
- L-Fucose alleviates Ochratoxin A-induced spermatogenic impairment: association with gut microbiota alterations.
Sun Z, Liu Y, Ding M, et al. · Environ Int 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.